Development and validation of a noninvasive prediction model for nonalcoholic steatohepatitis resolution after lifestyle intervention.

UNLABELLED: Liver biopsy is the gold standard method to assess nonalcoholic steatohepatitis (NASH) resolution after therapeutic interventions. We developed and validated a simple and noninvasive scoring system to predict NASH resolution without fibrosis worsening after 1 year of lifestyle intervention. This was a prospective cohort study conducted in 261 patients with histologically proven NASH who were treated with lifestyle changes for 52 weeks and underwent a second liver biopsy to confirm NASH resolution. We divided the data into development (140 subjects) and validation (121 individuals) sets. NASH resolution occurred in 28% (derivation group) and 27% (validation group). At the multivariable analysis, weight loss (odds ratio [OR] = 2.75, 95% confidence interval [CI] 1.65-4.58; P < 0.01), type 2 diabetes (OR = 0.04, 95% CI 0.005-0.49; P = 0.01), normal levels of alanine aminotransferase at the end of intervention (OR = 9.84, 95% CI 2.21-44.1; P < 0.01), age (OR = 0.89, 95% CI 0.83-0.97; P = 0.01), and a nonalcoholic fatty liver activity score ≥5 (OR = 0.08, 95% CI 0.01-0.43; P < 0.01) were independent predictors of NASH resolution. The area under the receiver operating characteristic curve of the selected model was 0.956 and 0.945 in the derivation and validation cohorts, respectively. Using a score threshold of ≤46.15, negative predictive values were 92% in the derivation and validation groups, respectively. By applying a cutoff ≥69.72, positive predictive values were 92% and 89% in the derivation and validation groups, respectively. Using both cutoffs, a liver biopsy would have been avoided in 229 (88%) of 261 patients, with a correct prediction in 209 (91%) CONCLUSIONS: A noninvasive prediction model including weight loss, type 2 diabetes, alanine aminotransferase normalization, age, and a nonalcoholic fatty liver activity score ≥5 may be useful to identify NASH resolution in patients under lifestyle intervention. (Hepatology 2016;63:1875-1887).

Infección oculta y coinfección viral en pacientes con hepatopatía crónica por virus B / Occult infection and viral co-infection in chronic hepatitis B patients

Introducción: la infección por el virus de la hepatitis B constituye uno de los principales problemas de salud a nivel mundial, su espectro clínico es variable.Objetivo: Identificar infección oculta y coinfección viral en pacientes con hepatopatía crónica por virus B. Material y Métodos: se realizó un estudio observacional descriptivo transversal en pacientes con hepatitis B crónica con carga viral detectable, atendidos durante el último trimestre de 2014 en el Instituto de Gastroenterología. Se estimó la seroprevalencia de anti HVC y anti HIV así como la frecuencia de AgHBs, y Anti S, las asociaciones fueron evaluadas mediante el estadígrafo x2. Resultados: existió un predominio de las cargas virales bajas para 81.3 por ciento. El 28.7 por ciento de las muestras fueron AgHBs negativas, sugestivas de infección por virus oculto. Se detectaron niveles de protección frente al antígeno S en 20 % de los pacientes con carga viral baja. la coinfección a hepatitis C fue frecuente para 8.4 por ciento. Conclusiones: la infección oculta al virus de hepatitis B fue frecuente en las muestras procesadas en el Instituto de Gastroenterología, con asociación a coinfección al virus de hepatitis C(AU)

Introduction: infection with the hepatitis B virus is one of the major health problems worldwide, clinical spectrum is variable. Objective: to identify occult viral infection and co-infection in patients with chronic liver disease for virus B. Material and Methods: a cross-sectional observational study was conducted in patients with chronic hepatitis B with detectable viral load seen during the last quarter of 2014 in the Institute of Gastroenterology. The seroprevalence of anti HCV and anti HIV and the frequency of HBsAg and Anti S was estimated associations were evaluated using the x2 statistic. Results: there is a predominance of low viral loadsto81.3 percent. 28.7 percent of samples were HBsAg negative, suggestive of occult virus infection. Protective levels against the antigen S were detected in 20 percent of patients with low viral load.Hepatitis C coinfection was frequent for 8.4 percent. Conclusions: the occult infection hepatitis B virus is common in samples processed at the Institute of Gastroenterology with associated coinfection virus hepatitis C(AU)

[Nonalcoholic fatty liver disease. A current perspective]. / Enfermedad hepática por depósitos grasos. Una perspectiva actual.

A review about nonalcoholic fatty liver disease is presented, considering the updated aspects related to pathophysiology, diagnosis and management of this medical condition.

Enfermedad hepática por depósitos grasos. Una perspectiva actual. / [Nonalcoholic fatty liver disease. A current perspective].

A review about nonalcoholic fatty liver disease is presented, considering the updated aspects related to pathophysiology, diagnosis and management of this medical condition.

Enfermedad hepática por depósitos grasos. Una perspectiva actual / [Nonalcoholic fatty liver disease. A current perspective].

A review about nonalcoholic fatty liver disease is presented, considering the updated aspects related to pathophysiology, diagnosis and management of this medical condition.

Viusid, a nutritional supplement, increases survival and reduces disease progression in HCV-related decompensated cirrhosis: a randomised and controlled trial.

OBJECTIVES: Viusid is a nutritional supplement with recognised antioxidant and immunomodulatory properties which could have beneficial effects on cirrhosis-related clinical outcomes such as survival, disease progression and development of hepatocellular carcinoma (HCC). This study evaluated the efficacy and safety of viusid in patients with HCV-related decompensated cirrhosis. DESIGN: A randomised double-blind and placebo-controlled study was conducted in a tertiary care academic centre (National Institute of Gastroenterology, Havana, Cuba). The authors randomly assigned 100 patients with HCV-related decompensated cirrhosis to receive viusid (three oral sachets daily, n=50) or placebo (n=50) during 96 weeks. The primary outcome of the study was overall survival at 96 weeks, and the secondary outcomes included time to disease progression, time to HCC diagnosis, time to worsening of the prognostic scoring systems Child-Pugh and Model for End-Stage Liver Disease, and time to a new occurrence or relapse for each one of the main clinical complications secondary to portal hypertension at 96 weeks. RESULTS: Viusid led to a significant improvement in overall survival (90%) versus placebo (74%) (HR 0.27, 95% CI 0.08 to 0.92; p=0.036). A similar improvement in disease progression was seen in viusid-treated patients (28%), compared with placebo-treated patients (48%) (HR 0.47, 95% CI 0.22 to 0.89; p=0.044). However, the beneficial effects of viusid were wholly observed among patients with Child-Pugh classes B or C, but not among patients with Child-Pugh class A. The cumulative incidence of HCC was significantly reduced in patients treated with viusid (2%) as compared with placebo (12%) (HR 0.15, 95% CI 0.019 to 0.90; p=0.046). Viusid was well tolerated. CONCLUSIONS: The results indicate that treatment with viusid leads to a notable improvement in overall clinical outcomes such as survival, disease progression and development of HCC in patients with HCV-related decompensated cirrhosis. Trial registration number http://ClinicalTrials.gov (NCT00502086).